000 | 01863 a2200505 4500 | ||
---|---|---|---|
005 | 20250514215956.0 | ||
264 | 0 | _c20051005 | |
008 | 200510s 0 0 eng d | ||
022 | _a1527-9995 | ||
024 | 7 |
_a10.1016/j.urology.2004.09.041 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aKong, Chuize | |
245 | 0 | 0 |
_aInhibition of tumor angiogenesis during cisplatin chemotherapy for bladder cancer improves treatment outcome. _h[electronic resource] |
260 |
_bUrology _cFeb 2005 |
||
300 |
_a395-9 p. _bdigital |
||
500 | _aPublication Type: Comparative Study; Journal Article | ||
650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadministration & dosage |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAntibiotics, Antineoplastic _xadministration & dosage |
650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xadministration & dosage |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
650 | 0 | 4 | _aApoptosis |
650 | 0 | 4 |
_aCarcinoma, Transitional Cell _xblood supply |
650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
650 | 0 | 4 | _aCombined Modality Therapy |
650 | 0 | 4 | _aCyclohexanes |
650 | 0 | 4 | _aDrug Screening Assays, Antitumor |
650 | 0 | 4 | _aDrug Synergism |
650 | 0 | 4 | _aInjections, Intraperitoneal |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aNeovascularization, Pathologic _xdrug therapy |
650 | 0 | 4 | _aO-(Chloroacetylcarbamoyl)fumagillol |
650 | 0 | 4 | _aRandom Allocation |
650 | 0 | 4 | _aRats |
650 | 0 | 4 |
_aSesquiterpenes _xadministration & dosage |
650 | 0 | 4 |
_aUrinary Bladder Neoplasms _xblood supply |
700 | 1 | _aZhu, Yuyan | |
700 | 1 | _aSun, Changcheng | |
700 | 1 | _aLi, Zeliang | |
700 | 1 | _aSun, Zhixi | |
700 | 1 | _aZhang, Xianghua | |
700 | 1 | _aTakanaka, Ikusama | |
773 | 0 |
_tUrology _gvol. 65 _gno. 2 _gp. 395-9 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.urology.2004.09.041 _zAvailable from publisher's website |
999 |
_c15384053 _d15384053 |